Leishmaniasis

Lancet. 2018 Sep 15;392(10151):951-970. doi: 10.1016/S0140-6736(18)31204-2. Epub 2018 Aug 17.

Abstract

Leishmaniasis is a poverty-related disease with two main clinical forms: visceral leishmaniasis and cutaneous leishmaniasis. An estimated 0·7-1 million new cases of leishmaniasis per year are reported from nearly 100 endemic countries. The number of reported visceral leishmaniasis cases has decreased substantially in the past decade as a result of better access to diagnosis and treatment and more intense vector control within an elimination initiative in Asia, although natural cycles in transmission intensity might play a role. In east Africa however, the case numbers of this fatal disease continue to be sustained. Increased conflict in endemic areas of cutaneous leishmaniasis and forced displacement has resulted in a surge in these endemic areas as well as clinics across the world. WHO lists leishmaniasis as one of the neglected tropical diseases for which the development of new treatments is a priority. Major evidence gaps remain, and new tools are needed before leishmaniasis can be definitively controlled.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiprotozoal Agents / therapeutic use*
  • Coinfection / complications
  • Disease Vectors
  • Global Health
  • HIV Infections / complications
  • Humans
  • Leishmania
  • Leishmaniasis, Cutaneous* / diagnosis
  • Leishmaniasis, Cutaneous* / drug therapy
  • Leishmaniasis, Cutaneous* / epidemiology
  • Leishmaniasis, Cutaneous* / physiopathology
  • Leishmaniasis, Visceral* / diagnosis
  • Leishmaniasis, Visceral* / drug therapy
  • Leishmaniasis, Visceral* / epidemiology
  • Leishmaniasis, Visceral* / physiopathology

Substances

  • Antiprotozoal Agents